| Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised … T Conroy, JF Bosset, PL Etienne, E Rio, É François, N Mesgouez-Nebout, ... The Lancet Oncology 22 (5), 702-715, 2021 | 753 | 2021 |
| Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a … T Conroy, N Lamfichekh, PL Etienne, E Rio, E Francois, ... Journal of Clinical Oncology 38 (15_suppl), 4007-4007, 2020 | 188 | 2020 |
| Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a … T Conroy, PL Etienne, E Rio, L Evesque, N Mesgouez-Nebout, ... Journal of Clinical Oncology 41 (17_suppl), LBA3504-LBA3504, 2023 | 66 | 2023 |
| Clinical and genetic landscape of treatment naive cervical cancer: alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome S Scholl, M Popovic, A de La Rochefordiere, E Girard, S Dureau, ... EBioMedicine 43, 253-260, 2019 | 47 | 2019 |
| Outcome according to elective pelvic radiation therapy in patients with high-risk localized prostate cancer: a secondary analysis of the GETUG 12 phase 3 randomized trial P Blanchard, L Faivre, F Lesaunier, N Salem, N Mesgouez-Nebout, ... International Journal of Radiation Oncology* Biology* Physics 94 (1), 85-92, 2016 | 29 | 2016 |
| Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer I Masson, L Larriviere, MA Mahé, D Azria, P Pommier, ... Clinical and Translational Radiation Oncology 44, 100702, 2024 | 2 | 2024 |
| Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy … L Ah-Thiane, L Campion, N Allouache, E Meyer, P Pommier, ... European Urology Oncology, 2024 | 1 | 2024 |
| Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study I Masson, M Bellanger, G Perrocheau, MA Mahé, D Azria, P Pommier, ... Frontiers in Oncology 11, 781121, 2022 | 1 | 2022 |
| Corrigendum to ‘clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome’ S Scholl, M Popovic, A de la Rochefordiere, E Girard, S Dureau, A Mandic, ... EBioMedicine 57, 2020 | 1 | 2020 |
| ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases. S Oudard, P Combe, T Boisserie, A Hasbini, T Leroy, S Supiot, U Schick, ... Journal of Clinical Oncology 42 (16_suppl), TPS5127-TPS5127, 2024 | | 2024 |
